Placebo Effect Challenges Healthcare’s Reputation Yields Returns
Healthcare’s reputation as a defensive sector has come under fresh scrutiny, with analysts suggesting the perceived safety may be more a “placebo effect” than a guarantee of stable returns.
Investors are re‑evaluating the label.
Related: Life Insurance Premiums: Where Does the Money Go
Why the defensive label is being questioned
Historically, demand for products such as respiratory support devices, plasma therapies, sleep‑apnoea masks and cochlear implants has shown resilience against typical business‑cycle swings. In 2026, on days when the MSCI World IT index fell about 2 % or more, global healthcare outperformed tech by roughly 3 % on average.
Nevertheless, the sector has not been a safe haven. Throughout most of 2025 it lagged, trading about 30 % below global equities in August – the widest discount in over a decade – before a modest rebound in the fourth quarter. Into 2026 the sector ranked among the weakest S&P sectors year‑to‑date, with earnings multiples near historic lows.
Analysts argue that the defensive promise bundles two ideas: steady sales and cash flow that survive macro‑economic downturns, and share‑price resilience that investors pay a premium for. When market perception shifts and prices fall, the expected protection can evaporate, leaving investors with a soothing narrative but little actual defense.
Related: The Woman Who Refused to Accept Limits: The Inspiring Story of Ruzanna Tikhova
Four companies illustrate the mixed picture
CSL, a long‑standing healthcare compounder, entered 2026 from a position of strength but saw its stock halve after policy and competitive shocks hit its immunoglobulin, albumin and iron franchises. A US$1.1 b intellectual‑property impairment and a US$2.1 b restructuring charge marked the year, yet Behring’s operating margin expanded and management launched a transformation program targeting US$500‑550 m of annual savings by FY28.
ResMed posted solid operating results. FY25 revenue grew across its franchise, gross margins rose about 6 % over two and a half years, and free‑cash‑flow conversion stayed above 100 %. The share‑price pressure stemmed from external concerns, such as the potential impact of GLP‑1 weight‑loss drugs on the sleep‑apnoea market and the prospect of renewed competition from Philips. Despite these worries, the company’s operating metrics continued to compound.
